Heart failure & cardiomyopathies
Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients
Authors' conclusion
Cardiac biomarker CR represents the deepest level of cardiac biochemical recovery in AL amyloidosis and is associated with survival similar to the general population.
Study context
- Population
- Patients with AL cardiac amyloidosis diagnosed 2004–2023 eligible for cardiac biomarker response (baseline NT-proBNP >650 pg/mL or BNP >150 pg/mL)63 achieved cardiac biomarker complete response (CR)
- Participants
- 1,342 patients
- Outcome
- Cardiac biomarker CR (NT-proBNP ≤350 pg/mL or BNP ≤80 pg/mL sustained ≥12 months): presentation, treatment, cardiac recovery and survival
- Follow-up
- Median 9.5 years
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Cardiac biomarker CR
- Cardiac biomarker CR achieved (63 of 1,342 evaluable)
- 4.7%
- Survival of CR patients vs matched general US population: comparable
- P = 0.35
- Deaths among CR patients (2 of non-AL cardiac amyloidosis (CA)-related causes)
- 8
Observational data: associations, not effects.
Further findings
Cardiac biomarker CR by period
P < 0.001
- Cardiac biomarker CR by period: denominators 591 vs 751
Characteristics and course of CR patients
- Median time to cardiac biomarker CR
- 20.6 months
- Median NT-proBNP at CR
- 265 pg/mL
- NT-proBNP reduction from baseline at CR
- 86.9%
- Median pretreatment NT-proBNP
- 1,977 pg/mL
- Hematologic CR preceded cardiac biomarker CR
- 76%
- Cardiac progression
- 14%
- Required subsequent clone-directed therapy
- 44.4%
- Echocardiographic parameters improved but did not fully normalize in all patients
Original publication
Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients. JACC CardioOncol. Published April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →